ATAI Life Sciences NV
NASDAQ:ATAI

Watchlist Manager
ATAI Life Sciences NV Logo
ATAI Life Sciences NV
NASDAQ:ATAI
Watchlist
Price: 1.19 USD Market Closed
Market Cap: 199.7m USD
Have any thoughts about
ATAI Life Sciences NV?
Write Note

Relative Value

The Relative Value of one ATAI stock under the Base Case scenario is 0.02 USD. Compared to the current market price of 1.19 USD, ATAI Life Sciences NV is Overvalued by 98%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ATAI Relative Value
Base Case
0.02 USD
Overvaluation 98%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
53
vs Industry
1
Median 3Y
946.8
Median 5Y
891.7
Industry
2.5
Forward
353.2
vs History
vs Industry
Median 3Y
-3
Median 5Y
-3.1
Industry
21.8
Forward
-1.4
vs History
vs Industry
Median 3Y
-3.6
Median 5Y
-3.9
Industry
16.1
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-3.9
Industry
23.8
vs History
37
vs Industry
58
Median 3Y
1.4
Median 5Y
1.5
Industry
2.1
vs History
20
vs Industry
1
Median 3Y
391.3
Median 5Y
359.6
Industry
2.7
Forward
237.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.2
vs History
vs Industry
57
Median 3Y
-1.5
Median 5Y
-1.5
Industry
13.5
Forward
-1.3
vs History
vs Industry
54
Median 3Y
-1.5
Median 5Y
-1.5
Industry
16.8
Forward
-1.3
vs History
vs Industry
55
Median 3Y
-2
Median 5Y
-2.4
Industry
15.2
vs History
vs Industry
41
Median 3Y
-2
Median 5Y
-2.4
Industry
19.3
vs History
58
vs Industry
56
Median 3Y
2.2
Median 5Y
2.9
Industry
1.9

Multiples Across Competitors

ATAI Competitors Multiples
ATAI Life Sciences NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
ATAI Life Sciences NV
NASDAQ:ATAI
199.7m USD 603.3 -1.6 -1.3 -1.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 17.8 87.1 46.9 52.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK 9.6 27.5 19.1 21.8
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
248.3B USD 3.9 20.4 10.3 12.4
CH
Roche Holding AG
SIX:ROG
197.2B CHF 3.4 17.2 9.7 11.5
UK
AstraZeneca PLC
LSE:AZN
159B GBP 4.1 31 169.2 253.5
CH
Novartis AG
SIX:NOVN
169.7B CHF 3.8 10.8 9.4 13
US
Pfizer Inc
NYSE:PFE
149.4B USD 2.5 35.1 10.5 15.8
P/S Multiple
Revenue Growth P/S to Growth
DE
ATAI Life Sciences NV
NASDAQ:ATAI
Average P/S: 382 996.7
603.3
-3%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
17.8
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
3.9
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
DE
ATAI Life Sciences NV
NASDAQ:ATAI
Average P/E: 31.6
Negative Multiple: -1.6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
87.1
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
27.5
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.4
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.2
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.1
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
ATAI Life Sciences NV
NASDAQ:ATAI
Average EV/EBITDA: 459.2
Negative Multiple: -1.3
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.9
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.3
331%
0
CH
Roche Holding AG
SIX:ROG
9.7
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.2
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
ATAI Life Sciences NV
NASDAQ:ATAI
Average EV/EBIT: 2 010.8
Negative Multiple: -1.3
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
21.8
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.5
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.5
131%
1.9
CH
Novartis AG
SIX:NOVN
13
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2

See Also

Discover More
Back to Top